Insider Selling: Compugen (NASDAQ:CGEN) SVP Sells 5,375 Shares of Stock

Key Points

• Zurit Levine, Compugen's SVP, sold 5,375 shares on April 8 at an average price of $2.42 under a pre-arranged Rule 10b5-1 plan, reducing her stake to 29,375 shares (a 15.47% decrease).
• CGEN shares rose about 8.3% to $2.48 on higher-than-average volume, trading near a 1-year high with a market cap of roughly $234 million and 50/200-day moving averages of $1.98/$1.80.
• Compugen posted a strong quarter on March 2 with EPS of $0.60 vs. $0.05 expected and revenue of $67.33M, and analysts maintain a consensus "Moderate Buy" with an average price target of $5.00.

Compugen Ltd. (NASDAQ:CGEN - Get Free Report) SVP Zurit Levine sold 5,375 shares of the business's stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $2.42, for a total value of $13,007.50. Following the completion of the transaction, the senior vice president directly owned 29,375 shares in the company, valued at approximately $71,087.50. This represents a 15.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zurit Levine also recently made the following trade(s):

• On Tuesday, April 7th, Zurit Levine sold 2,500 shares of Compugen stock. The stock was sold at an average price of $2.30, for a total value of $5,750.00.
• On Wednesday, April 1st, Zurit Levine sold 3,500 shares of Compugen stock. The stock was sold at an average price of $2.20, for a total value of $7,700.00.

Compugen Stock Up 8.3%

CGEN stock traded up $0.19 during midday trading on Thursday, hitting $2.48. The company's stock had a trading volume of 434,359 shares, compared to its average volume of 373,808. The stock's 50-day moving average price is $1.98 and its 200 day moving average price is $1.80. Compugen Ltd. has a 1 year low of $1.15 and a 1 year high of $2.49. The stock has a market cap of $234.48 million, a price-to-earnings ratio of 6.70 and a beta of 2.77.

Compugen (NASDAQ:CGEN - Get Free Report) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.55. Compugen had a return on equity of 55.68% and a net margin of 48.57%.The business had revenue of $67.33 million for the quarter, compared to analysts' expectations of $14.30 million. As a group, equities analysts forecast that Compugen Ltd. will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Compugen

Hedge funds have recently made changes to their positions in the company. Bank Hapoalim BM bought a new stake in shares of Compugen in the fourth quarter valued at $37,000. Security National Bank of Sioux City Iowa IA bought a new stake in shares of Compugen in the fourth quarter valued at $38,000. Franklin Resources Inc. bought a new stake in shares of Compugen in the second quarter valued at $56,000. Osaic Holdings Inc. raised its stake in shares of Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company's stock valued at $78,000 after purchasing an additional 34,045 shares during the period. Finally, WINTON GROUP Ltd bought a new stake in shares of Compugen during the 4th quarter valued at $84,000. 12.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on CGEN shares. Wall Street Zen raised Compugen from a "hold" rating to a "buy" rating in a research report on Saturday, March 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Compugen in a research note on Wednesday, January 21st. Truist Financial upgraded Compugen to a "strong-buy" rating in a research note on Wednesday, March 25th. HC Wainwright initiated coverage on Compugen in a research note on Wednesday, January 7th. They issued a "buy" rating and a $4.00 target price on the stock. Finally, Lake Street Capital initiated coverage on Compugen in a research note on Tuesday. They issued a "buy" rating and a $6.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $5.00.

Compugen Company Profile

Compugen Ltd. NASDAQ: CGEN is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.